OpGen Inc (NASDAQ:OPGN) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Wednesday.

According to Zacks, “OpGen, Inc. is a microbial genetics analysis company. The Company offers optical mapping services for analysis of microbial, yeast and fungal genomic architecture. OpGen, Inc. headquartered in Gaithersburg, Maryland. “

Separately, Rodman & Renshaw set a $3.30 price objective on shares of OpGen and gave the company a “buy” rating in a research report on Wednesday, August 10th.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/12/opgen-inc-opgn-upgraded-to-hold-by-zacks-investment-research.html

Shares of OpGen (NASDAQ:OPGN) opened at 1.61 on Wednesday. The company has a 50 day moving average price of $1.66 and a 200 day moving average price of $1.61. OpGen has a 12-month low of $1.02 and a 12-month high of $4.65. The firm’s market cap is $34.88 million.

OpGen (NASDAQ:OPGN) last posted its quarterly earnings data on Tuesday, August 9th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by $0.09. On average, analysts forecast that OpGen will post ($1.17) earnings per share for the current fiscal year.

About OpGen

OpGen, Inc (OpGen) is a developer of precision medicine tools. The Company uses molecular testing and bioinformatics to help guide antibiotic therapy and to assist healthcare providers to combat multi-drug resistant infections (MDROs). The Company’s lead products include the QuickFISH and PNAFISH products, which are in vitro diagnostic kits for the diagnosis and prevention of infectious diseases; the Acuitas MDRO Gene Test, which is a lab-based test that provides a profile of MDRO resistant genes from patients screened for colonization or infection, and the Acuitas Lighthouse, which is used to aid in the interpretation of MDRO diagnostic test results.

5 Day Chart for NASDAQ:OPGN

Get a free copy of the Zacks research report on OpGen (OPGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OpGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.